BeyondSpring Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
FY EPS (est.)
$1.98next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Third-Quarter 2026 Financial Results | 15 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Short-Term Investments Quarterly7.9M
DUBLIN-4 Confirmatory Phase 3 Trial Target Enrollment AnnuallyTarget: 442 patients
Quarterly Net Loss from Continuing Operations Quarterly-2.4M
Watch Items
- DUBLIN-4 Confirmatory Phase 3 Trial ProgressTrigger: First patient dosed or enrollment milestones reachedAction: Monitor clinical trial registry updates (NCT07361484) and corporate press releases for execution speed.
- NASDAQ Continued Listing ComplianceTrigger: Failure to meet minimum bid price or shareholders' equity requirementsAction: Review SEC filings and corporate announcements regarding compliance plans or potential reverse stock splits.
- SEED Therapeutics ST-01156 Phase 1a Trial ProgressTrigger: Completion of first dose cohort or safety/efficacy readoutsAction: Track clinical updates from SEED Therapeutics' RBM39 molecular glue degrader program.
Research as of 19 Jun 2026